PURPOSE: The purpose of this study was to evaluate the quality of life (QOL) of patients receiving treatment by the public health system in Brazil for chronic myeloid leukemia (CML), a disease requiring daily and strict compliance to oral medication and regular blood and bone marrow controls, which are invasive exams. METHODS: Between 2008 and 2010, patients with CML were surveyed by telephone. Quality of life was evaluated by the functional assessment of chronic illness therapy (FACIT) tool. RESULTS: The mean QOL among CML patients was 92.53 (out of 124 total points) in the trial outcome index, 78.50 (out of 108) in the general total score, and 130.43 (out of 176) in the leukemia total score. Patients who had the prescriptions recently changed anyway had better QOL general score (p = 0.012) and leukemia-specific score (p = 0.043) than those who remained with the same treatment. Imatinib was not associated with this change in QOL (p > 0.797). The more the patient felt able to work, the higher the scores in all three FACIT scales (p < 0.001, Spearman's correlation). The use of imatinib (p = 0.012) was associated with a better ability to work, while chemotherapy (p = 0.017) and the use of hydroxyurea (p = 0.001) were inversely associated with work capability. CONCLUSIONS: A recent change in medication can improve quality of life. The ability to work is an important component of quality of life of patients with CML. Ability to work should be specifically considered in CML treatment.
PURPOSE: The purpose of this study was to evaluate the quality of life (QOL) of patients receiving treatment by the public health system in Brazil for chronic myeloid leukemia (CML), a disease requiring daily and strict compliance to oral medication and regular blood and bone marrow controls, which are invasive exams. METHODS: Between 2008 and 2010, patients with CML were surveyed by telephone. Quality of life was evaluated by the functional assessment of chronic illness therapy (FACIT) tool. RESULTS: The mean QOL among CMLpatients was 92.53 (out of 124 total points) in the trial outcome index, 78.50 (out of 108) in the general total score, and 130.43 (out of 176) in the leukemia total score. Patients who had the prescriptions recently changed anyway had better QOL general score (p = 0.012) and leukemia-specific score (p = 0.043) than those who remained with the same treatment. Imatinib was not associated with this change in QOL (p > 0.797). The more the patient felt able to work, the higher the scores in all three FACIT scales (p < 0.001, Spearman's correlation). The use of imatinib (p = 0.012) was associated with a better ability to work, while chemotherapy (p = 0.017) and the use of hydroxyurea (p = 0.001) were inversely associated with work capability. CONCLUSIONS: A recent change in medication can improve quality of life. The ability to work is an important component of quality of life of patients with CML. Ability to work should be specifically considered in CML treatment.
Authors: Kathleen J Yost; Mark V Sorensen; Elizabeth A Hahn; G Alastair Glendenning; Ari Gnanasakthy; David Cella Journal: Value Health Date: 2005 Mar-Apr Impact factor: 5.725
Authors: F Efficace; M Baccarani; M Breccia; F Cottone; G Alimena; G L Deliliers; C Baratè; G Specchia; R Di Lorenzo; L Luciano; D Turri; B Martino; F Stagno; M Dabusti; M Bergamaschi; P Leoni; M P Simula; L Levato; C Fava; D Veneri; S Sica; A Rambaldi; G Rosti; M Vignetti; F Mandelli Journal: Leukemia Date: 2013-02-18 Impact factor: 11.528
Authors: Stephanie J Lee; Manisha Kukreja; Tao Wang; Sergio A Giralt; Jeffrey Szer; Mukta Arora; Ann E Woolfrey; Francisco Cervantes; Richard E Champlin; Robert Peter Gale; Joerg Halter; Armand Keating; David I Marks; Philip L McCarthy; Eduardo Olavarria; Edward A Stadtmauer; Manuel Abecasis; Vikas Gupta; H Jean Khoury; Biju George; Gregory A Hale; Jane L Liesveld; David A Rizzieri; Joseph H Antin; Brian J Bolwell; Matthew H Carabasi; Edward Copelan; Osman Ilhan; Mark R Litzow; Harold C Schouten; Axel R Zander; Mary M Horowitz; Richard T Maziarz Journal: Blood Date: 2008-07-29 Impact factor: 22.113
Authors: André Gulinelli; Rubens K Aisawa; Sérgio N Konno; Christian V Morinaga; Wagner L Costardi; Rodrigo O Antonio; Rodrigo B Dumarco; Renata M Moino; Márcio Katz; Sandro Giavarotti; Allan P Z Skarbnik; Cyntia S Forcione; Toshio Chiba; Mílton A Martins Journal: Rev Assoc Med Bras (1992) Date: 2004 Jan-Mar Impact factor: 1.209
Authors: Washington Batista das Neves; Ana Maria de Brito; Andreza Pâmela Vasconcelos; Fárida Coeli de Barros Correia Melo; Raul Antônio Morais Melo Journal: Hematol Transfus Cell Ther Date: 2019-03-28